Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
50 Northern Avenue
Boston, MA 02210
(617) 341-6100Website: https://www.vrtx.com/Careers: https://vrtx.wd5.myworkdayjobs.com...Patient Assistance Program: https://www.vrtx.com/medicines...
Latest News
- Vertex Announces U.S. FDA Approval for Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations - June 9, 2021
- Vertex Announces FDA Approvals of Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor), Symdeko (tezacaftor/ivacaftor and ivacaftor) and Kalydeco (ivacaftor) for Use in People With CF With Certain Rare Mutations - December 21, 2020
- FDA Approves Kalydeco (ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants With CF as Early as Four Months of Age - September 25, 2020
- FDA Approves Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for Cystic Fibrosis Patients Ages 12 and Older Who Have at Least One F508del Mutation - October 21, 2019
- FDA Accepts New Drug Application for VX-445 (Elexacaftor), Tezacaftor and Ivacaftor Combination Treatment - August 20, 2019
- Vertex Submits New Drug Application to the U.S. FDA for Triple Combination Regimen of VX-445 (Elexacaftor), Tezacaftor and Ivacaftor in Cystic Fibrosis - July 22, 2019
- FDA Approves Symdeko (tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of CF in Children Ages 6-11 Years with Certain Mutations in the CFTR Gene - June 21, 2019
- Vertex Selects Triple Combination Regimen of VX-445, Tezacaftor and Ivacaftor to Submit for Global Regulatory Approvals in Cystic Fibrosis - May 30, 2019
- FDA Approves Kalydeco (ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants with CF as Early as Six Months of Age - April 30, 2019
- FDA Approves Kalydeco (ivacaftor) for Cystic Fibrosis in Children Ages 12 to <24 Months with Certain Mutations in the CFTR Gene - August 15, 2018
Drugs Associated with Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated manufactures, markets and/or distributes more than 4 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.
Brand/Generic Name | Reviews | Rating |
---|---|---|
Kalydeco
Generic name: ivacaftor Drug class: CFTR potentiators |
1 review | 10 / 10 |
Orkambi
Generic name: ivacaftor/lumacaftor Drug class: CFTR combinations |
||
Symdeko
Generic name: ivacaftor/tezacaftor Drug class: CFTR combinations |
||
Trikafta
Generic name: elexacaftor/ivacaftor/tezacaftor Drug class: CFTR combinations |
1 review | 9.0 / 10 |
For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective). |